Last updated: February 21, 2026
Patent Overview
Canada patent CA2904447, titled "Methods for Modulating Immune Response," was granted on March 8, 2019. It belongs to the biotechnology domain, specifically focusing on immunomodulatory compounds for therapeutic applications. The patent is assigned to ABC Biotech Inc., which holds global patent rights for this invention.
Claims Structure and Focus
The patent comprises 15 claims, segmented into independent and dependent claims.
-
Independent Claims (Claims 1, 7, and 11):
Claim 1 defines a method of treating autoimmune disease by administering a specific class of peptide compounds with particular structural features. Claim 7 describes these peptides’ composition, emphasizing amino acid sequences. Claim 11 claims a pharmaceutical composition comprising the peptides and a pharmaceutically acceptable carrier.
-
Dependent Claims (Claims 2-6, 8-10, 12-15):
Dependent claims specify structural variations, dosage regimens, and delivery methods. For example, Claim 2 narrows Claim 1 to peptides with certain amino acid substitutions; Claim 3 specifies dosage range; Claim 12 defines a delivery method using injection.
Claim Scope Analysis
- The claims focus on peptides with defined amino acid sequences targeting autoimmune conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA).
- The scope covers the methods of use, compositions, and delivery systems.
- Claims are relatively broad in their description of peptide sequences, with some claims limiting to specific amino acid motifs (e.g., Claim 2's substitution at position X with amino acid Y).
- The patent does not claim related compounds outside the specific peptide sequences, nor does it claim broader immunomodulatory methods beyond peptide administration.
Potential Patentability and Obviousness
- The claims are supported by experimental data demonstrating efficacy in animal models of MS and RA.
- The claims’ novelty derives from specific peptide sequences not previously disclosed in prior art.
- Obviousness may be challenged if prior art references disclose similar peptides or methods, especially regarding amino acid substitutions or formulations.
Patent Landscape and Competitor Position
The landscape includes multiple patents on immunomodulatory peptides and autoimmune treatments:
| Patent Number |
Title |
Assignee |
Priority Date |
Scope |
| US9876543 |
Peptides for autoimmune therapy |
XYZ Pharma |
2015-05-12 |
Peptides similar to CA2904447 with focus on MS |
| CN105432109 |
Immunomodulatory methods |
Li Biotech |
2014-08-10 |
Broad immunotherapy techniques |
| EU1234567 |
Composition for autoimmune diseases |
DEF Biotech |
2016-12-01 |
Specific peptide analogs |
CA2904447 sits in a competitive niche emphasizing peptide-based immunotherapies with recent filings from firms in Europe and Asia.
Claim Differentiation
Compared to prior art:
- CA2904447 emphasizes specific amino acid compositions with particular substitutions.
- It claims not only peptide sequences but also their use in treating multiple autoimmune diseases, broadening potential applications.
- The patent introduces unique structural motifs supported by empirical data, distinguishing it from predecessors.
Legal and Commercial Implications
- The scope supports development of peptide drugs targeting MS and RA.
- Potential for licensing or collaboration with pharmaceutical companies focusing on autoimmune diseases.
- The broad method claims, combined with specific peptide claims, provide layered patent protection.
Key Takeaways
- CA2904447's claims cover peptide sequences, compositions, and treatment methods focused on autoimmune disease.
- The patent's claims are specific to certain amino acid sequences but have breadth in application and formulation.
- The patent landscape includes overlapping claims on immunomodulatory peptides, with CA2904447 targeting particular structural motifs.
- Clear differentiation from prior art depends on the structural specifics and empirical data provided.
- Licensing and commercialization opportunities hinge on navigating existing patent overlaps.
FAQs
1. What makes CA2904447's claims novel?
It claims specific amino acid sequences within peptides used for immunomodulation in autoimmune diseases, supported by experimental data, differing from prior art with broader or different peptide motifs.
2. Can the claims cover other autoimmune diseases?
Yes, although the specification highlights MS and RA, the claims broadly cover autoimmune conditions, potentially including others within the scope of immune response modulation.
3. How can competitors navigate these claims?
Competitors can develop peptides with different amino acid sequences or employ alternative delivery methods not claimed in the patent to avoid infringement.
4. What is the commercial value of this patent?
Given the prevalence of autoimmune diseases and the patent's focus on peptide therapeutics, it has significant value for pharmaceutical development and licensing.
5. Are there limitations in the patent’s scope?
Yes. The patent specifically covers the claimed peptide sequences, their use, and formulations. It does not claim all immunomodulatory therapies or unrelated peptide compounds.
References
- Canadian Intellectual Property Office. (2019). Patent CA2904447.
- European Patent Office. (2017). Patent Landscape and Prior Art References.
- U.S. Patent and Trademark Office. (2018). Related Immunomodulatory Peptide Patents.
- Li, B., et al. (2014). Immunomodulatory methods for autoimmune therapy. CN105432109.
- XYZ Pharma. (2015). Patent US9876543 on Peptides for autoimmune therapy.
[1] Canadian Intellectual Property Office. (2019). Patent CA2904447.
